文献速递眼整形与眼眶

近年泪腺腺样囊性癌患者的疾病特异性生存与总生存

Disease-specific and overall survival for patients with lacrimal gland adenoid cystic carcinoma in recent decades.
PubMed 文献 · Br J Ophthalmol · 2026-01-22

这项回顾性单中心队列研究纳入1998年11月至2024年8月连续治疗的52例泪腺腺样囊性癌患者,评估其症状、总生存与疾病特异性生存。疼痛仅见于33%患者,保眼手术者5年及10年疾病特异性生存率均优于眶内容物剜除者,基底样组织学亚型生存更差。

要点

  • 疼痛仅出现在33%的泪腺腺样囊性癌患者中。
  • 保眼手术者5年及10年疾病特异性生存率分别为87.1%和76.2%,优于眶内容物剜除者的62.3%和57.5%(p=0.049)。
  • 基底样(实性)组织学亚型较非基底样亚型疾病特异性生存更差(p=0.00057)。

核心结论

  • 疼痛仅见于约三分之一泪腺腺样囊性癌患者。
  • 本组5年及10年疾病特异性生存率与总生存率优于既往报道的历史数据。

研究设计与样本

  • 回顾性单中心队列研究,纳入1998年11月至2024年8月由第一作者连续治疗的52例泪腺腺样囊性癌患者。

主要发现

  • 52例患者中位年龄43.5岁(范围9-71岁),疼痛见于17例(33%)。
  • 26例(50%)接受眶内容物剜除,25例(48%)接受保眼手术,保眼手术自2007年起仅选择性地用于部分患者。
  • 47例(90%)接受术后放疗,18例(35%)发生远处转移,末次随访时14例(27%)死于疾病(中位随访60个月)。
  • 保眼手术者5年及10年疾病特异性生存率分别为87.1%和76.2%,优于眶内容物剜除者的62.3%和57.5%(p=0.049)。
  • 基底样(实性)亚型较非基底样亚型疾病特异性生存更差(p=0.00057)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the presenting symptoms, and the overall survival (OS) and disease-specific survival (DSS) in patients with lacrimal gland adenoid cystic carcinoma (LGACC). METHODS: This retrospective single-centre cohort study included all consecutive patients with LGACC treated by the primary author from November 1998 through August 2024. Demographic data, presenting symptoms, the histological subtype of LGACC, type of surgical treatment, adjuvant radiotherapy or chemotherapy, T category at presentation and survival data were reviewed. Correlations between histological subtypes, T-category, type of surgery (eye sparing vs orbital exenteration), and DSS and OS were analysed. RESULTS: 52 patients had a median age of 43.5 years (range: 9-71). Pain was the most common symptom but was only present in 17 patients (33%), 26 patients (50%) had orbital exenteration and 25 (48%) had eye-sparing surgery. Eye-sparing surgery was offered to selected patients only since 2007. Overall, 47 patients (90%) had postoperative radiotherapy and 18 patients (35%) developed distant metastasis. At last contact, 14 patients (27%) had died of disease (median follow-up=60 months). The 5-year and 10-year DSS rates for patients who had eye-sparing surgery (87.1% and 76.2%, respectively) were better than for patients who had orbital exenteration (62.3% and 57.5%, respectively, p=0.049). There was a significant difference between the DSS for basaloid (solid) versus non-basaloid histologic subtypes with a worse survival for basaloid histology (p=0.00057). CONCLUSIONS: Pain was present in only one-third of patients with LGACC. The 5-year and 10-year DSS and OS rates are better than previously reported 'historic data'.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Esmaeli B, Li Z, Lu TJ, et al. Disease-specific and overall survival for patients with lacrimal gland adenoid cystic carcinoma in recent decades. Br J Ophthalmol. 2026. PMID: 40866108. doi:10.1136/bjo-2025-327745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。